ANNUAL GENERAL MEETING

==> picture [112 x 112] intentionally omitted <==

23 NOVEMBER 2017

==> picture [329 x 70] intentionally omitted <==

Maria Halasz CEO & Managing Director

==> picture [31 x 25] intentionally omitted <==

IMPORTANT NOTICE

==> picture [196 x 44] intentionally omitted <==

Forward looking statements

This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this presentation. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of advertising, sales activities and competition.

CELLMID (CDY:ASX)

==> picture [196 x 43] intentionally omitted <==

Fully Paid Ordinary Shares (22 November 2017)

1,068,456,303

Market Capitalisation (22 November 2017)

A$ 21 million

Unlisted options

32,500,000

Cash Position (30 September 2017)

A$ 3.85 million

Debt ($2 million due Feb 2019, secured against R&D Tax Credit)

A$ 2.0 million

CORPORATE AND BUSINESS STRUCTURE

==> picture [249 x 55] intentionally omitted <==

==> picture [166 x 87] intentionally omitted <==

LYRA MID KINE RA

Novel FGF5 inhibitor hair growth products sold as OTC, non-prescription natural medicines and cosmetics

Midkine antibodies for the treatment of fibrosis, chronic kidney disease and cancer

Midkine protein for the treatment of postischemic conditions including heart failure

==> picture [98 x 98] intentionally omitted <==

==> picture [97 x 97] intentionally omitted <==

==> picture [108 x 113] intentionally omitted <==

Dr David King | Chairman

An experienced independent chairman with expertise in high growth companies, David has a track record in building business ventures and developing them into attractive take-over targets.

Maria Halasz| CEO and Managing Director

With over 24 years in the life sciences sector Maria started in corporate finance before joining Cellmid ten years ago as CEO. Maria led the acquisition of the company’s current portfolio of midkine and FGF5 inhibitor assets.

Dr Martin Cross | Non-Executive Director

Dr Cross is a highly regarded pharmaceutical executive with over 30 years’ experience in industry leadership roles as Chairman of Medicines Australia, Country Head and Managing Director of Novartis Australia and Managing Director of Alphapharm.

==> picture [97 x 98] intentionally omitted <==

==> picture [100 x 96] intentionally omitted <==

BOARD MEMBERS

==> picture [196 x 43] intentionally omitted <==

Bruce Gordon | Non-Executive Director

Bruce is a seasoned audit partner and corporate finance specialist with over 35 years’ industry experience. Bruce brings significant expertise in valuations, mergers and acquisitions, restructuring and transaction support.

Dr Fintan Walton | Non-Executive Director

Fintan has over 33 years experience in the global pharmaceutical and biotechnology sectors and is the founder and CEO of PharmaVentures Ltd, a leading UK based corporate advisory firm.

FINANCIAL PERFORMANCE

==> picture [196 x 44] intentionally omitted <==

Financial Results 2014-2017	2014	2015	2016	2017
Total revenue and other income	$ 1,898,037	$ 2,930,518	$ 4,611,108	$ 5,560,121
Consumer health revenue	$ 1,150,931	$ 1,842,804	$ 2,962,306	$ 4,453,208
Midkine and license revenue	$ 1,009,188	$ 99,263	$ 205,390	$ 247,606
R&D tax credit/grants	$ 747,106	$ 988,451	$ 1,121,562	$ 831,408
Total expenditure	$ 5,023,890	$ 6,301,547	$ 8,098,979	$ 9,530,994
R&D spending	$ 1,660,236	$ 2,196,558	$ 2,124,360	$ 2,176,925
Current assets	$ 4,499,891	$ 4,173,616	$ 5,131,104	$ 6,562,302
Sales Revenue/Expenditure*	23%	29%	36%	46%

CONSUMER HEATH REVENUE 2014 – 2017

Consumer Health Revenue

==> picture [196 x 43] intentionally omitted <==

==> picture [382 x 13] intentionally omitted <==

----- Start of picture text -----

2014 2015 2016 2017
----- End of picture text -----

TOTAL REVENUE 2014 – 2017

==> picture [574 x 379] intentionally omitted <==

----- Start of picture text -----

Total Revenue
2014 2015 2016 2017
----- End of picture text -----

==> picture [196 x 44] intentionally omitted <==

==> picture [866 x 451] intentionally omitted <==

Targets for 2017	Achieved in FY2017
évolis® Professional retail partnership in the US	Signed Neiman Marcus partnership on 3 August 2017 with online launch on 1 September 2017 and stores in mid 2018. Additional retail groups are expected to come on line.
Grow direct customer base to 10,000	Currently customer data base of around 7,000 with plans to initiate a campaign to increase this once the new évolis® website is completed.
Increase QVC Japan sales	FY2016 HIGHLIGHTS Sales in this channel continued to increase during FY2017 with an overall Japanese revenue increase from $2.1 million in FY2016 to $3.0 million in FY2017.
Open concept store in Japan in late 2017	Hair Biology concept store opened on 25 October 2017 and expected to become profitable by mid 2018
Increase sell through in Australian pharmacies and broaden distribution	Increased per store sales and reduced below the line marketing costs in the pharmacy channel, increasing overall sales from $812K in FY2016 to $1.46 million in FY2017 and opening the road to profitability
Expand distribution to other geographical regions	Resumed Lexilis sales in China Continued progress on Chinese e-commerce strategy Commenced sales in New Zealand and internationally on e-commerce platform

Additional milestones achieved	Additional milestones achieved
US distribution partnership with Colour Collective	The partnership for the development, branding and marketing of the évolis® Professional product range was formed and as a result, three new product ranges (REVERSE, PROMOTE and PREVENT) were developed and launched in the US during the FY2017 financial year
Quarterly sales exceeded $1 million for the first time in Q1 FY2017	Since October 2016 quarterly sales have been consistently on or above $1 million for the consumer health business
US midkine patent granted for alopecia	~~FY2016 HIGHLIGHTS~~ The Company’s assets grew with another midkine alopecia patent in the US, a major potential market
US consumer experience study was completed	The study had 79 participants testing the entire évolis® Professional product range. This was the first study when participants used the Activator, Shampoo and Conditioner as a three-step system to resolve multiple hair challenges
Chinese import permits received	Import permit for Lexilis and Jo-Ju have been received and shipping to China resumed.
FGF5 inhibitor clinical study published	Published clinical study data and FGF5 inhibitory assays in the journal _Clinical, Cosmetic and Investigational Dermatology_in Marc 2017. The paper describes the results of the 32 patient, blinded and placebo controlled study and the selective assays used to identify FGF5 inhibitors
	11 for the Company’s products.

Key objectives FY2018 and beyond

==> picture [152 x 81] intentionally omitted <==

Develop and launch new évolis® website. Building a global website with improved sales capabilities, potential for subscription and better customer data management, which is expected to result in an increase in e-commerce sales in Australia, the USA and China.

Continue to build retail partnerships. Targeting continued growth in the number of retail partnerships for the évolis® Professional range in the US and Australia, the évolis® pharmacy range in the US, Australia and Japan and the Jo-Ju and Lexilis brands in Japan and China.

Grow the professional salon business. Increase penetration into the barbershop/salon market in all three geographical FY2016 HIGHLIGHTS regions. Although the business models and margins are different, accessing the stylists, the hair experts, to represent the FGF5 inhibitor products is a key target.

Increase international sales. Primarily via e-commerce we expect to implement targeted sales campaigns to specific markets in Asia and Europe.

Continue research and development. As a key element in product leadership, and the most significant differentiating factor, we expect to continue research in hair biology and active ingredients with the view to publish new data. To that end our partnerships with research and commercial groups will play a critical part.

Continue innovation and product development. Planning to launch three new products by the end of 2018 which can be included in the pharmacy and the professional ranges.

RESULTS OF CONSUMER USAGE STUDY

==> picture [221 x 244] intentionally omitted <==

==> picture [240 x 246] intentionally omitted <==

==> picture [217 x 215] intentionally omitted <==

100% 97% 96% Of users experienced Of users saw an Of users experienced less hair fall improvement in hair new hair growth texture

Of users experienced new hair growth

==> picture [229 x 210] intentionally omitted <==

87% Of users improved their position on the Hamilton Norwood/Ludwig Scales

==> picture [25 x 26] intentionally omitted <==

30 days 60 days 90 days 120 days Never

==> picture [104 x 44] intentionally omitted <==

==> picture [107 x 46] intentionally omitted <==

In a 2017 Consumer Usage Study of 67 users conducted by Colour Collective, Dallas TX13

==> picture [18 x 85] intentionally omitted <==

==> picture [18 x 83] intentionally omitted <==

==> picture [18 x 84] intentionally omitted <==

==> picture [18 x 76] intentionally omitted <==